Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. (2021)
Attributed to:
Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.21.01436
PubMed Identifier: 34516759
Publication URI: http://europepmc.org/abstract/MED/34516759
Type: Journal Article/Review
Volume: 39
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 33
ISSN: 0732-183X